Amber L Bahorik1, Amy Leibowitz2, Stacy A Sterling2, Adam Travis3, Constance Weisner4, Derek D Satre4. 1. Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, 401 Parnassus Avenue, Box 0984, San Francisco, CA 94143, USA; Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, 3rd Floor, Oakland, CA 94612, USA. Electronic address: amber.bahorik@ucsf.edu. 2. Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, 3rd Floor, Oakland, CA 94612, USA. 3. Kaiser Permanente Southern Alameda Department of Psychiatry, USA. 4. Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, 401 Parnassus Avenue, Box 0984, San Francisco, CA 94143, USA; Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, 3rd Floor, Oakland, CA 94612, USA.
Abstract
BACKGROUND: Depression is associated with substance-related problems that worsen depression-related disability. Marijuana is frequently used by those with depression, yet whether its use contributes to significant barriers to recovery in this population has been understudied. METHOD: Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial. Longitudinal growth models examined patterns and predictors of marijuana use and its impact on symptom and functional outcomes. RESULTS: A considerable number of (40.7%; n=125) patients used marijuana within 30-days of baseline. Over 6-months, marijuana use decreased (B=-1.20, p<.001), but patterns varied by demographic and clinical characteristics. Depression (B=0.03, p<.001) symptoms contributed to increased marijuana use over the follow-up, and those aged 50+(B=0.44, p<.001) increased their marijuana use compared to the youngest age group. Marijuana use worsened depression (B=1.24, p<.001) and anxiety (B=0.80, p=.025) symptoms; marijuana use led to poorer mental health (B=-2.03, p=.010) functioning. Medical marijuana (26.8%; n=33) was associated with poorer physical health (B=-3.35, p=.044) functioning. LIMITATIONS: Participants were psychiatry outpatients, limiting generalizability. CONCLUSIONS: Marijuana use is common and associated with poor recovery among psychiatry outpatients with depression. Assessing for marijuana use and considering its use in light of its impact on depression recovery may help improve outcomes.
BACKGROUND:Depression is associated with substance-related problems that worsen depression-related disability. Marijuana is frequently used by those with depression, yet whether its use contributes to significant barriers to recovery in this population has been understudied. METHOD:Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial. Longitudinal growth models examined patterns and predictors of marijuana use and its impact on symptom and functional outcomes. RESULTS: A considerable number of (40.7%; n=125) patients used marijuana within 30-days of baseline. Over 6-months, marijuana use decreased (B=-1.20, p<.001), but patterns varied by demographic and clinical characteristics. Depression (B=0.03, p<.001) symptoms contributed to increased marijuana use over the follow-up, and those aged 50+(B=0.44, p<.001) increased their marijuana use compared to the youngest age group. Marijuana use worsened depression (B=1.24, p<.001) and anxiety (B=0.80, p=.025) symptoms; marijuana use led to poorer mental health (B=-2.03, p=.010) functioning. Medical marijuana (26.8%; n=33) was associated with poorer physical health (B=-3.35, p=.044) functioning. LIMITATIONS: Participants were psychiatry outpatients, limiting generalizability. CONCLUSIONS:Marijuana use is common and associated with poor recovery among psychiatry outpatients with depression. Assessing for marijuana use and considering its use in light of its impact on depression recovery may help improve outcomes.
Authors: Tarja K Melartin; Heikki J Rytsälä; Ulla S Leskelä; Paula S Lestelä-Mielonen; T Petteri Sokero; Erkki T Isometsä Journal: J Clin Psychiatry Date: 2002-02 Impact factor: 4.384
Authors: Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan Journal: Arch Gen Psychiatry Date: 2004-08
Authors: Jacqueline M Smith; Joel Mader; Andrew C H Szeto; Amelia M Arria; Ken C Winters; T Chris R Wilkes Journal: Can J Psychiatry Date: 2019-01-02 Impact factor: 4.356
Authors: Aaron L Sarvet; Melanie M Wall; Katherine M Keyes; Mark Olfson; Magdalena Cerdá; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2018-03-02 Impact factor: 4.492
Authors: Deborah S Hasin; Aaron L Sarvet; Jacquelyn L Meyers; Tulshi D Saha; W June Ruan; Malka Stohl; Bridget F Grant Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Amber L Bahorik; Cynthia I Campbell; Stacy A Sterling; Amy Leibowitz; Adam Travis; Constance M Weisner; Derek D Satre Journal: Psychiatry Res Date: 2017-10-19 Impact factor: 3.222